The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data


Cite item

Full Text

Abstract

Aim of the issue was to compare clinical characteristics and treatment results of patients with follicular lymphoma (FL) with translocations involving loci of c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes and patients with high - grade B-cell lymphoma [High - grade B-cell lymphoma (HGBL), double - hit (DH)]. Materials and methods. Since 2004 to 2017 years in National Research Center for Hematology 12 patients with high - grade B-cell lymphoma double - hit (HGBL DH) and 6 FL patients with translocations involving c-MYC and BCL2 and/or BCL6 had been treated. We performed a comparative analysis of clinical characterisctics in both groups. As primary endpoints was assessed frequency of complete remission (CR) or progressive disease (PD); as secondary endpoints - overall (OS) and event - free survival (EFS). Results. 5 patients with HGBL DH had c-MYC/BCL6, 7 - c-MYC/BCL2 rearrangements; 2 patients with FL had c-MYC/BCL2, 3 - c-MYC/BCL6, 1 - c-MYC/BCL2/BCL6 rearrangements. FL was represented by grade 3A in 2, grade 3B - in 4 cases, 3 of them had large - cell transformation. In HGBL DH and FL patients had no significant differences in clinical characteristics. The majority of patients had a widespread tumour, increased LDH activity, high frequency of extranodal and bone marrow involvement. Ki-67 expression level was lower in patients with FL (p<0.05). Patients with HGBL DH were treated with R-BL-M-04, R-(DA)-EPOCH, CHOP-21±R, with FL - R-CHOP-21 or R-(DA)-EPOCH. Frequency of CR in HGBL DH and FL was 42% and 33%, respectively. Frequency of PD was 50% in both groups. Two - year OS of patients with HGBL DH and FL harbouring c-MYC, BCL2 and/or BCL6 rearrangements was 50% and 42% respectively, p=0.85. Two - year EFS was 33% in both groups, p=0.8. Conclusions. We presented highly aggressive variant of FL grade 3 harbouring c-MYC, BCL2 and/or BCL6 rearrangements that had similarly poor prognosis as patients with HGBL DH.

About the authors

A E Misyurina

National Research Center for Hematology

Email: anna.lukina1@gmail.com
к.м.н., врач-гематолог отд-ния интенсивной высокодозной химиотерапии гемобластозов с круглосуточным и дневным стационаром ФГБУ «НМИЦ гематологии» Минздрава России Moscow, Russia

S K Kravchenko

National Research Center for Hematology

к.м.н., зав. отд-нием интенсивной высокодозной химиотерапии гемобластозов с круглосуточным и дневным стационаром ФГБУ «НМИЦ гематологии» Минздрава России Moscow, Russia

A M Kovrigina

National Research Center for Hematology

д.б.н., проф., зав. патологоанатомическим отд-нием ФГБУ «НМИЦ гематологии» Минздрава России Moscow, Russia

A U Magomedova

National Research Center for Hematology

д.м.н., в.н.с. отд-ния интенсивной высокодозной химиотерапии гемобластозов с круглосуточным и дневным стационаром ФГБУ «НМИЦ гематологии» Минздрава России Moscow, Russia

L V Plastinina

National Research Center for Hematology

к.м.н., врач-гематолог консультативного гематологического отд-ния с дневным стационаром по проведению интенсивной высокодозной химиотерапии ФГБУ «НМИЦ гематологии» Минздрава России Moscow, Russia

T N Obukhova

National Research Center for Hematology

к.м.н., зав. лаб. кариологии ФГБУ «НМИЦ гематологии» Минздрава России Moscow, Russia

A V Misyurin

Blokhin National Medical Cancer Research Center

д.б.н., зав. лаб. рекомбинантных опухолевых антигенов ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России Moscow, Russia

V A Misyurin

Blokhin National Medical Cancer Research Center

к.б.н., с.н.с. лаб. экспериментальной диагностики и биотерапии опухолей ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России Moscow, Russia

L A Grebenuk

National Research Center for Hematology

лабораторный генетик лаб. кариологии ФГБУ «НМИЦ гематологии» Минздрава России Moscow, Russia

F E Babaeva

National Research Center for Hematology

врач-гематолог отд-ния интенсивной высокодозной химиотерапии гемобластозов круглосуточным и дневным стационаром ФГБУ «НМИЦ гематологии» Минздрава России Moscow, Russia

E A Baryakh

City Clinical Hospital №52

врач-гематолог отд-ния гематологии и интенсивной терапии ГКБ №52 Moscow, Russia

A I Vorobiev

National Research Center for Hematology

акад. РАН, д.м.н., проф., главный н.с. отд-ния интенсивной высокодозной химиотерапии гемобластозов с круглосуточным и дневным стационаром ФГБУ «НМИЦ гематологии» Минздрава России Moscow, Russia

References

  1. Aukema S.M, Siebert R, Schuuring E, van Imhoff G.W, Kluin-Nelemans H.C, Boerma E.J, Kluin P.M. Double - hit B-cell lymphomas. Blood. 2011;117:2319-31. doi: 10.1182/blood-2010-09-297879
  2. Мисюрин А.В. Основы молекулярной диагностики онкогематологических заболеваний. Российский биотерапевтический журнал. 2016;15(4):18-24. doi: 10.17650/1726-9784-2016-15-4-18-24
  3. Li S, Lin P, Young K.H, Kanagal-Shamanna R, Yin C.C, Medeiros L.J. MYC/BCL2 double - hit high - grade B-Cell lymphoma. Advances in anatomic pathology. 2013;20:315-26. doi: 10.1097/PAP.0b013e3182a289f2
  4. Johnson N.A, Savage K.J, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer M.J, Siebert R, Kuruvilla J, Klasa R, Connors J.M, Gascoyne R.D, Horsman D.E. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114:2273-9. doi: 10.1182/blood-2009-03-212191
  5. Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, Gaillard F, Gastinne T, Milpied N, Moreau P, Harousseau J.L, Avet-Loiseau H. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92:1335-42. doi: 10.3324/haematol.11305
  6. Lin P, Medeiros L.J. High - grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica. 2007;92:1297-301. doi: 10.3324/haematol.11263
  7. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23:777-83. doi: 10.1038/leu.2008.344
  8. Pedersen M.O, Gang A.O, Poulsen T.S, Knudsen H, Lauritzen A.F, Nielsen S.L, Gang U.O, Norgaard P. Double - hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single center's experience. European J Hematology. 2012;89:63-71. doi: 10.1111/j.1600-0609.2012.017 87.x
  9. Snuderl M, Kolman O.K, Chen Y.B, Hsu J.J, Ackerman A.M, Dal Cin P, Ferry J.A, Harris N.L, Hasserjian R.P, Zukerberg L.R, Abramson J.S, Hochberg E.P, Lee H, Lee A.I, Toomey C.E, Sohani A.R. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. American J Surgical Pathology. 2010;34:327-40. doi: 10.1097/ PAS.0b013e3181cd3aeb
  10. Барях Е.А., Мисюрина А.Е., Ковригина А.М., Мисюрин В.А., Кравченко С.К. B-клеточная лимфома, неклассифицируемая, занимающая промежуточное положение между диффузной B-крупноклеточной лимфомой и лимфомой Беркитта. Терапевтический архив. 2015;87(4):91-7. doi: 10.17116/terarkh201587491-97
  11. Ji M, Jang S, Lee J.H, Seo E.J. Double - hit myeloma with IGH/MYC and IGH/CCND1 translocations. Ann Hematol. 2013;92(8):1129-31. doi: 10.1007/ s00277-012-1668-y
  12. Hao S, Sanger W, Onciu M, Lai R, Schlette E.J, Medeiros L.J. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol. 2002;15:1266-72. doi: 10.1097/01.MP.0000 037310.82136.99
  13. Huh Y.O, Lin K.I, Vega F, Schlette E, Yin C.C, Keating M.J, Luthra R, Medeiros L.J, Abruzzo L.V. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol. 2008;142:36-44. doi: 10.1111/j.1365-2141.2008.07152.x
  14. Mohamed A.N, Palutke M, Eisenberg L, Al-Katib A. Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant. Cancer Genetics and Cytogenetics. 2001;126:45-51.
  15. Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott M.M, Kalla J, Romero M, Siebert R, Rosenwald A, Ott G. Follicular lymphoma grade 3b is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011;96(9):1327-34. doi: 10.3324/haematol.2011.042531
  16. Bosga-Bouwer A.G, van den Berg A, Haralambieva E, de Jong D, Boonstra R, Kluin P, van den Berg E, Poppema S. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol. 2006;37(5):528-33. doi: 10.1016/j.hum path.2005.12.005
  17. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122(24):3884-91. doi: 10.1182/blood-2013-05-498329
  18. Korac P, Dotlic S, Domins M. "Double hit" lymphoma or secondary MYC translocation lymphoma? Period biol. 2012;114(4):527-37. doi: 10.3390/genes 8040115
  19. Macpherson N, Lesack D, Klasa R, Horsman D, Connors J.M, Barnett M, Gascoyne R.D. Small Noncleaved, Non-Burkitt's (Burkitt-Like) Lymphoma: Cytogenetics Predict Outcome and Reflect Clinical Presentation. J Clin Oncol. 1999;17(5):1558-67. doi: 10.1200/JCO.1999.17.5.1558
  20. Барях Е.А., Мисюрина А.Е., Ковригина А.М., Обухова Т.Н., Кравченко С.К., Магомедова А.У., Зингерман Б.В., Мисюрина Е.Н., Потешкина Н.Г., Лысенко М.А., Воробьев А.И. Клинические особенности и терапия double - hit и double - expressor лимфом. Современная онкология. 2016;18(5):22-30.
  21. Swerdlow S.H, Campo E, Harris N.L, Jaffe E.S, Pileri S.A, Stein H, Thiele J, Vardiman J.W. Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, Revised 4th Edition, Volume 2. Lyon: IARC Press, 2017.
  22. Momose S, Weißbach S, Pischimarov J, Nedeva T, Bach E, Rudelius M, Geissinger E, Staiger A.M, Ott G, Rosenwald A. The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia. 2015;29(8):1789-91. doi: 10.1038/ leu.2015.34
  23. Swerdlow S.H. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program. 2014;(1):90-9. doi: 10.1182/asheducation-2014.1.90
  24. Campo E. MYC in DLBCL: partners matter. Blood. 2015;126(22):2439-40. doi: 10.1182/blood-2015-10-671362
  25. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd H.W, Cogliatti S.B, Dierlamm J, Feller A.C, Hansmann M.L, Haralambieva E, Harder L, Hasenclever D, Kühn M, Lenze D, Lichter P, Martin-Subero J.I, Möller P, Müller-Hermelink H.K, Ott G, Parwaresch R.M, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szczepanowski M, Trautmann H, Wacker H.H, Spang R, Loeffler M, Trümper L, Stein H, Siebert R. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419-30. doi: 10.1056/NEJMoa055351
  26. Li S, Lin P, Fayad L.E, Lennon P.A, Miranda R.N, Yin C.C, Lin E, Medeiros L.J. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Modern Pathology. 2012;25:145-56. doi: 10.1038/modpathol.2011.147
  27. Cheah C.Y, Oki Y, Westin J.R, Turturro F. A clinician's guide to double hit lymphomas. Br J Haematol. 2015;168(6):784-95. doi: 10.1111/bjh.13276
  28. Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, Miyamoto K, Kikuchi A, Hyo R, Yakushijin Y, Masaki Y, Fujii S, Hayashi T, Ishigatsubo Y, Miura I. Clinicopathological features of lymphoma/ leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009; 94(7):935-43. doi: 10.3324/haematol.2008.005355
  29. Oki Y, Noorani M, Lin P, Davis R.E, Neelapu S.S, Ma L, Ahmed M, Rodriguez M.A, Hagemeister F.B, Fowler N, Wang M, Fanale M.A, Nastoupil L, Samaniego F, Lee H.J, Dabaja B.S, Pinnix C.C, Medeiros L.J, Nieto Y, Khouri I, Kwak L.W, Turturro F, Romaguera J.E, Fayad L.E, Westin J.R. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891-901. doi: 10.1111/bjh.12982
  30. Petrich A.M, Gandhi M, Jovanovic B, Castillo J.J, Rajguru S, Yang D.T, Shah K.A, Whyman J.D, Lansigan F, Hernandez-Ilizaliturri F.J, Lee L.X, Barta S.K, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens A.M, Shah N, Fenske T.S, Zelenetz A.D, Landsburg D.J, Howlett C, Mato A, Jaglal M, Chavez J.C, Tsai J.P, Reddy N, Li S, Handler C, Flowers C.R, Cohen J.B, Blum K.A, Song K, Sun H.L, Press O, Cassaday R, Jaso J, Medeiros L.J, Sohani A.R, Abramson J.S. Impact of induction regimen and stem cell transplantation on outcomes in double - hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354-61. doi: 10.1182/blood-20 14-05-578963
  31. Sun H, Savage K.J, Karsan A, Slack G.W, Gascoyne R.D, Toze C.L, Sehn L.H, Abou Mourad Y, Barnett M.J, Broady R.C, Connors J.M, Forrest D.L, Gerrie A.S, Hogge D.E, Narayanan S, Nevill T.J, Nantel S.H, Power M.M, Sutherland H.J, Villa D, Shepherd J.D, Song K.W. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. H Sun, Clinical Lymphoma, Myeloma & Leukemia. 2015; 15(6):341-8. doi: 10.1016/j.clml.2014.12.015
  32. Kanagal-Shamanna R, Medeiros L.J, Lu G, Wang S.A, Manning J.T, Lin P, Penn G.M, Young K.H, You M.J, Vega F, Bassett R, Miranda R.N. High - grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology. 2012;61(5):945-54. doi: 10.1111/j.1365-2559.2012.04301.x
  33. Li S, Saksena A, Desai P, Xu J, Zuo Z, Lin P, Tang G, Yin C.C, Seegmiller A, Jorgensen J.L, Miranda R.N, Reddy N.M, Bueso-Ramos C, Medeiros L.J. Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma. Oncotarget. 2016;7(25):38122-32. doi: 10.18632/oncotarget.9473
  34. Christie L, Kernohan N, Levison D, Sales M, Cunningham J, Gillespie K, Batstone P, Meiklejohn D, Goodlad J. C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator? Leuk lymphoma. 2008;49:470-6. doi: 10.1080/10428190701836845
  35. Yano T, Jaffe E.S, Longo D.L, Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood. 1992;80:758-67.
  36. Vafaii P, Shao H. “Double hit” follicular lymphoma with low proliferation index: A unique case and literature review. Adv Mod Oncol Res. 2017; 3(2):126-30. doi: 10.18282/amor.v3.i3.169
  37. Kanda-Akano Y, Nomura K, Fujita Y, Horiike S, Nishida K, Nagai M, Miura I, Nakamura S, Seto M, Iida S, Ueda R, Taniwaki M. Molecular - cytogenetic characterization of non-Hodgkin’s lymphoma with double and cryptic translocations of the immunoglobulin heavy chain gene. Leuk Lymphoma. 2004;45(8):1559-67. doi: 10.1080/10428190310001625674
  38. Voorhees P.M, Carder K.A, Smith S.V, Ayscue L.H, Rao K.W, Dunphy C.H. Follicular lymphoma with a Burkitt translocation - Predictor of an aggressive clinical course: A case report and review of the literature. Arch Pathol Lab Med. 2004;128(2):210-3. doi: 10.1043/1543-2165(2004)128<210:FLWABT> 2.0.CO;2
  39. Kanungo A, Medeiros L.J, Abruzzo L.V, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/ c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19(1):25-33. doi: 10.1038/mod pathol.3800500
  40. Miao Y, Hu S, Lu X, Li S, Wang W, Medeiros L.J, Lin P. Double - hit follicular lymphoma with MYC and BCL2 translocations: A study of 7 cases with a review of literature. Hum Pathol. 2016;58:72-7. doi: 10.1016/j.humpath. 2016.07.025
  41. Kridel R, Sehn L.H, Gascoyne R.D. Can Histologic Transformation of Follicular Lymphoma Be Predicted and Prevented? Blood. 2017;130(3):258-66. doi: 10.1182/blood-2017-03-691345
  42. Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes A.B, Ouillette P, Trifonov V, Rossi D, Tabbò F, Ponzoni M, Chadburn A, Murty V.V, Bhagat G, Gaidano G, Inghirami G, Malek S.N, Rabadan R, Dalla-Favera R. Genetics of Follicular Lymphoma Transformation. Cell Rep. 2014;6(1):130-40. doi: 10.1016/j.celrep.2013.12.027
  43. Lo Coco F, Gaidano G, Louie D.C, Offit K, Chaganti R.S, Dalla-Favera R. P53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 1993;82(8):2289-95.
  44. Sander C.A, Yano T, Clark H.M, Harris C, Longo D.L, Jaffe E.S, Raffeld M. P53 mutation is associated with progression in follicular lymphomas. Blood. 1993; 82(7):1994-2004.
  45. Au W.Y, Horsman D.E, Gascoyne R.D, Viswanatha D.S, Klasa R.J, Connors J.M. The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. Leuk Lymphoma. 2004;45(3):519-28.
  46. Lossos I.S, Alizadeh A.A, Diehn M, Warnke R, Thorstenson Y, Oefner P.J, Brown P.O, Botstein D, Levy R. Transformation of follicular lymphoma to diffuse large - cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA. 2002; 99(13):8886-91. doi: 10.1073/pnas.132253599
  47. Alhejaily A, Day A.G, Feilotter H.E, Baetz T, Lebrun D.P. Inactivation of the CDKN2A tumor suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome. Clin Cancer Res. 2014;20(6):1676-86. doi: 10.1158/1078-0432.CCR-13-2175
  48. Fitzgibbon J, Iqbal S, Davies A, O'shea D, Carlotti E, Chaplin T, Matthews J, Raghavan M, Norton A, Lister T.A, Young B.D. Genome - wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia. 2007;21(7):1514-20. doi: 10.1038/sj.leu.2404696
  49. Elenitoba-Johnson K.S, Gascoyne R.D, Lim M.S, Chhanabai M, Jaffe E.S, Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood. 1998;91(12):4677-85.
  50. Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez P.L, Montserrat E, Cardesa A, Campo E. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin’s lymphomas. Blood. 1998;91(8):2977-84.
  51. Vaidyanathan G, Ngamphaiboon N, Hernandez-Ilizaliturri F.J. Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature. Ann Hematol. 2011;90(8):955-62. doi: 10.1007/s00277-011-1162-y
  52. Natkunam Y, Warnke R.A, Zehnder J.L, Jones C.D, Milatovich-Cherry A, Cornbleet P.J. Blastic/Blastoid Transformation of Follicular Lymphoma: Immunohistologic and Molecular Analyses of Five Cases. Amer J Surgical Pathology. 2000;24(4):525-34.
  53. Нестерова Е.С., Кравченко С.К., Мангасарова Я.К., Барях Е.А., Мисюрина А.Е., Воробьев В.И., Пластинина Л.В., Чернова Н.Г., Ковригина А.М., Обухова Т.Н., Клясова Г.А., Шевелев А.А., Костина И.Э., Гемджян Э.Г., Гапонова Т.В., Воробьев А.И. Фолликулярная лимфома. Высокодозная иммунохимиотерапия с трансплантацией аутологичных стволовых клеток крови: результаты первого проспективного исследования в России. Терапевтический архив. 2016;88(7):62-71. doi: 10.17116/terarkh201688762-71
  54. Yunis J.J, Soreng A.L. Constitutive fragile sites and cancer. Science. 1984;226:1199-204.
  55. Thangavelu M, Olopade O, Beckman E, Vardiman J.W, Larson R.A, McKeithan T.W, Le Beau M.M, Rowley J.D. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24; q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990;2:147-58.
  56. Offit K, Jhanwar S.C, Ladanyi M, Filippa D.A, Chaganti R.S. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin’s lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer. 1991;3:189-201.
  57. Karsan A, Gascoyne R.D, Coupland R.W, Shepherd J.D, Phillips G.L, Horsman D.E. Combination of t(14;18) and a Burkitt’s type translocation in B-cell malignancies. Leuk Lymphoma. 1993;10;433-41.
  58. Stamatoullas A, Buchonnet G, Lepretre S, Lenain P, Lenormand B, Duval C, Callat M.P, Gaulard P, Bastard C, Tilly H. De novo acute B-cell leukemia/lymphoma with t(14;18). Leukemia. 2000;14:1960-6.
  59. Cohen J.B, Geyer S.M, Lozanski G, Zhao W, Heerema N.A, Hall N.C, Nagar V.A, Hemminger J.A, Jones J.A, Porcu P, Christian B.A, Baiocchi R.A, Maddocks K.J, Flynn J.M, Devine S.M, Blum K.A. Complete response to induction therapy in patients with Myc - positive and double - hit non-Hodgkin lymphoma is associated with prolonged progression - free survival. Cancer. 2014; 120(11):1677-85. doi: 10.1002/cncr.28642
  60. Boerma E.G, Siebert R, Kluin P.M, Baudis M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today’s knowledge. Leukemia. 2009;23(2):225-34. doi: 10.1038/leu.2008.281

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies